Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
[dedifferentiated liposarcoma]
A
promising
targeted
therapy
against
NY
-ESO-
1
(
CTAG
1
B
)
using
genetically
modified
T
-
cells
in
synovial
sarcomas
was
recently
demonstrated
in
a
clinical
trial
at
the
NCI
.
To
investigate
the
role
of
NY
-ESO-
1
immunohistochemistry
in
patient
selection
and
gain
better
insight
into
the
incidence
of
NY
-ESO-
1
expression
in
synovial
sarcomas
and
other
mesenchymal
tumors
,
we
evaluated
NY
-ESO-
1
expression
by
immunohistochemistry
in
417
tumors
.
This
collection
of
samples
included
:
50
SS
18
/
SSX
1
/
2
fusion
positive
synovial
sarcomas
,
155
gastrointestinal
stromal
tumors
(
GIST
)
,
135
other
spindle
cell
sarcomas
as
well
as
77
other
sarcomas
(
chondrosarcoma
,
osteosarcoma
,
dedifferentiated
liposarcoma
,
alveolar
soft
part
sarcoma
,
rhabdomyosarcoma
,
angiosarcoma
,
malignant
mesothelioma
,
and
Ewing
's
sarcoma
)
.
We
report
that
76
%
of
synovial
sarcomas
expressed
NY
-ESO-
1
in
a
strong
and
diffuse
pattern
(
2
-
3
+
,
>
50
-
70
%
of
tumor
cells
)
.
In
contrast
,
only
rare
cases
of
other
spindle
cell
mesenchymal
tumor
expressed
NY
-ESO-
1
(
GIST
(
2
/
155
)
,
malignant
peripheral
nerve
sheath
tumors
(
1
/
34
)
,
and
dermatofibrosarcoma
protuberans
(
2
/
20
)
)
.
Individual
cases
of
other
sarcomas
(
angiosarcoma
,
malignant
mesothelioma
,
chondrosarcoma
,
osteosarcoma
,
dedifferentiated
liposarcoma
,
alveolar
soft
part
sarcoma
,
and
Ewing
's
sarcoma
)
were
positive
for
NY
-ESO-
1
.
However
,
no
positive
cases
were
identified
amongst
our
cohort
of
leiomyosarcomas
(
0
/
24
)
,
hemangiopericytoma
/
solitary
fibrous
tumors
(
0
/
40
)
,
and
cellular
schwannomas
(
0
/
17
)
.
In
summary
,
we
find
that
NY
-ESO-
1
is
strongly
and
diffusely
expressed
in
a
majority
of
synovial
sarcomas
,
but
only
rarely
in
other
mesenchymal
lesions
.
Beyond
its
role
in
patient
selection
for
targeted
therapy
,
immunohistochemistry
for
NY
-ESO-
1
may
be
diagnostically
useful
for
the
distinction
of
synovial
sarcoma
from
other
spindle
cell
neoplasms
.
Diseases
Validation
Diseases presenting
"tumor cells"
symptom
alpha-thalassemia
carcinoma of the gallbladder
cholangiocarcinoma
cushing syndrome
dedifferentiated liposarcoma
dentin dysplasia
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
hodgkin lymphoma, classical
junctional epidermolysis bullosa
kindler syndrome
liposarcoma
lymphangioleiomyomatosis
pleomorphic liposarcoma
primary effusion lymphoma
severe combined immunodeficiency
triple a syndrome
von hippel-lindau disease
waldenström macroglobulinemia
well-differentiated liposarcoma
werner syndrome
wiskott-aldrich syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom